好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Risk of First Time Seizure After Stroke: A Large-Scale Controlled Cohort Study
Cerebrovascular Disease and Interventional Neurology
S47 - Stroke Outcomes and Recurrence (1:44 PM-1:55 PM)
005

New onset epilepsy is a known sequella of AIS. Prior studies have been limited by small sample size and characterization of timing and frequency is lacking.

The frequency and timing of seizure after acute ischemic stroke (AIS) is poorly defined. Improved understanding is necessary to guide the use of anti-epileptic medications after AIS.

Using administrative data on all Emergency Department and inpatient visits in Florida (2005-2015), we identified patients with first time stroke. AIS and seizure were defined using validated ICD9 codes. The primary endpoint was first time seizure within the study period was 4 years post stroke. Patients were excluded for prior trauma, seizure, tumors, hemorrhage. We used a case-crossover design in which each patient served as her own control, by matching the study period with a control period of time 4 year prior to the stroke, using multivariate conditional logistic regression. Results are presented as OR [95% CI] or mean ± SD.

Among 294,351 patients with first time AIS, mean age 71.7 (±14), 52% were female, 70% were white, 17% were African American, and 11% were Hispanic. First time seizure was observed in 4,637 patients (1.6%), on average 610 (± 581) days post stroke. In case-crossover analysis, the likelihood of first time seizure was significantly increased following stroke (OR=2.04 [1.86 - 2.23]).

First time seizure after AIS is relatively uncommon late consequence of stroke. However, in case-crossover analysis, first time AIS resulted in a nearly two-fold increase in likelihood of first time seizure.

Authors/Disclosures
Vivek Mehta, MD (UT Houston McGovern Medical School)
PRESENTER
Dr. Mehta has nothing to disclose.
Shaun O. Smart, MD Dr. Smart has nothing to disclose.
No disclosure on file
Sean I. Savitz, MD Dr. Savitz has nothing to disclose.
Louise D. McCullough, MD, PhD (McGovern Medical School, UTHealth) The institution of Dr. McCullough has received research support from NIH. The institution of Dr. McCullough has received research support from American Heart Association.
Farhaan S. Vahidy, MBBS, PhD (Houston Methodist) Dr. Vahidy has nothing to disclose.
Sunil Sheth, MD (University of Texas At Houston) Dr. Sheth has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Penumbra. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imperative Care.